New hope for ALK+ lung cancer: brigatinib trial underway

NCT ID NCT04318938

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the targeted drug brigatinib in 118 people with ALK-positive non-small cell lung cancer that has spread or cannot be surgically removed. The main goal is to see how long the cancer stays under control before it progresses. Researchers are also studying how the drug affects quality of life and the timing of next treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Brigatinib (a targeted cancer drug)
What this could lead to: If successful, this could provide a more effective first-line treatment option for people with ALK-positive lung cancer, potentially delaying disease progression.
What could go wrong: This is a mid-stage (Phase 2) trial with 118 participants, so results are not definitive. The drug may not outperform existing treatments or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Show contact details

Locations

Charité Berlin

Berlin, Germany
Evangelisches Krankenhaus Hamm

Hamm, Germany
HELIOS Klinikum Emil von Behring

Berlin, 14165, Germany
KRH Klinikum Siloah Hannover

Hanover, 30459, Germany
Klinik Schillerhöhe

Stuttgart, Germany
Klinik der LMU München - Innenstadt

München, Germany
Klinikum Esslingen

Esslingen am Neckar, 73730, Germany
Klinikum Nürnberg

Nuremberg, 90419, Germany
Krankenhaus Nordwest Frankfurt

Frankfurt am Main, 60488, Germany
Lungenklinik Hemer

Hemer, Germany
Lungenklinik Köln - Merheim

Cologne, 51109, Germany
Medizinische Hochschule Hannover

Hanover, Germany
Niels-Stensen-Kliniken Georgsmarienhütte

Georgsmarienhütte, 49124, Germany
Pius Hospital Oldenburg

Oldenburg, 26121, Germany
Studiengesellschaft Hämato-Onkologie Hamburg

Hamburg, 20251, Germany
Thoraxklinik am Universitätsklinikum Heidelberg

Heidelberg, 69126, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany
Universitätsklinikum Gießen

Giessen, Germany
Universitätsklinikum Jena

Jena, 07740, Germany
Universitätsklinikum Leipzig

Leipzig, 04103, Germany
Universitätsklinikum Münster

Münster, Germany
Universitätsklinikum Regensburg

Regensburg, 93053, Germany
Universitätsklinikum Ulm

Ulm, 89081, Germany
Universitätsklinikum Würzburg

Würzburg, Germany
Universitätsmedizin Essen

Essen, 45147, Germany
Universitätsmedizin Mainz

Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.